Intel stock spikes after report of possible US government stake
Director Michael W. Dunne of Iterum Therapeutics PLC (NASDAQ:ITRM) has recently purchased 15,000 ordinary shares of the company. The transaction, which occurred on August 8, 2025, involved the acquisition of shares at a price of $0.7236, for a total value of $10,854. The purchase comes as the stock trades near $0.71, down nearly 50% over the past six months, with technical indicators suggesting oversold conditions according to InvestingPro analysis.
Following this transaction, Dunne directly owns 235,001 ordinary shares of Iterum Therapeutics, representing a notable stake in this $31.89M market cap company. InvestingPro offers deeper insights into insider trading patterns and 10+ additional key metrics in its comprehensive Pro Research Report, helping investors make more informed decisions.
In other recent news, Iterum Therapeutics has secured a Product Commercialization Agreement with Eversana Life Science Services for its approved product, ORLYNVAH™, in the United States. The agreement, signed on June 6, 2025, involves Eversana providing services such as sales, marketing, logistics, and regulatory support, while Iterum will handle legal, regulatory, and manufacturing responsibilities. Additionally, Iterum announced a renegotiated payment agreement with Pfizer (NYSE:PFE), extending a $20 million regulatory milestone payment related to ORLYNVAH™ from October 2026 to October 25, 2029. This milestone payment was part of a previous license agreement between Iterum and Pfizer, linked to the FDA approval of ORLYNVAH™. The antibiotic is designed to treat uncomplicated urinary tract infections in adult women. These developments highlight Iterum’s strategic efforts in managing financial obligations and expanding the commercialization of its products.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.